GlassScriptPhysician profile
Frank D Jones
NPI 1447246608
$14,133.07
in general payments reported to CMS, 2019-2025
51 companies · $2,539 in 2025
The $2,539 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,142 · 2020: $898 · 2021: $1,525 · 2022: $1,844 · 2023: $2,362 · 2024: $2,824 · 2025: $2,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,708 · Education: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,708.02 |
| Education | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,511.91 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,232.49 | 2019-2025 | |
| Abbvie INC. | $1,140.98 | 2019-2025 | |
| Astellas Pharma US INC | $1,061.03 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $1,057.15 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $924.19 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $870.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $780.58 | 2019-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $717.27 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.85 | 2019-2025 | Jardiance, Ofev |
| E.R. Squibb & Sons, L.L.C. | $389.45 | 2019-2025 | Eliquis, Camzyos |
| Shield Therapeutics INC | $364.44 | 2023-2025 | Accrufer |
| Dexcom, INC. | $354.35 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $285.19 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Novartis Pharmaceuticals Corporation | $251.44 | 2019-2023 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.